Form 4: Schrodinger CFO Geoffrey Craig Porges Reports Stock Transactions

EVP & CFO of Schrodinger, Geoffrey Craig Porges, reports acquisition and disposal of common stock and stock options, including vesting of restricted stock units and sales to cover tax liabilities.

Summary

• Geoffrey Craig Porges, EVP & CFO of Schrodinger, Inc., filed a Form 4 detailing changes in beneficial ownership.
• On March 3, 2025, Porges acquired 12,500 restricted stock units (RSUs) and 14,850 performance-based restricted stock units (PRSUs) at $0.
• Also on March 3, 2025, Porges sold 5,491 shares of common stock at $21.76 per share to cover withholding tax liabilities related to the vesting of PRSUs.
• Porges was also granted a stock option to purchase 50,000 shares at an exercise price of $21.24, vesting in installments from March 3, 2026, through March 3, 2029.
• Following these transactions, Porges beneficially owns 27,544 shares of common stock and holds options for 50,000 shares.

Sentiment

Score: 6

Explanation: Neutral sentiment as the transactions appear routine and pre-planned. The vesting of PRSUs is a positive sign, but the sale of shares, even for tax purposes, tempers the overall sentiment.

Positives

• The grant of RSUs and PRSUs indicates continued alignment of executive compensation with company performance.
• The vesting of PRSUs suggests achievement of certain performance metrics, which is a positive indicator for the company.

Negatives

• The sale of shares, even for tax purposes, could be perceived negatively by some investors, although it was pre-planned under a 10b5-1 plan.

Risks

• Future vesting of RSUs and stock options is contingent on continued service with the company.
• Fluctuations in the stock price could impact the value of the stock options and RSUs.

Future Outlook

Future vesting of RSUs and stock options is dependent on continued service with the company, aligning executive incentives with long-term performance.

Industry Context

Executive stock transactions are common in publicly traded companies and are closely monitored by investors for insights into management's confidence in the company's future prospects. The use of 10b5-1 plans is a standard practice to avoid insider trading allegations.

Comparison to Industry Standards

• Stock option grants and RSU awards are typical components of executive compensation packages in the biotech and software industries, aligning executive incentives with shareholder value.
• Companies like Moderna and BioNTech also utilize similar equity-based compensation plans for their executives.
• The vesting schedules and performance-based components are generally in line with industry practices to retain key personnel and drive performance.

Stakeholder Impact

• Shareholders may view the vesting of PRSUs positively, indicating achievement of performance goals.
• Employees may be motivated by the alignment of executive compensation with company performance.

Key Dates